Osmotic drug delivery system: A review
Osmotic drug delivery uses the osmotic pressure level for controlled delivery of drugs by using osmogens. Osmotic systems for controlled drug-delivery applications are well established, both in human pharmaceuticals and in veterinary medicine. The process of osmosis is that can control the drug delivery system. Osmotic pressure created from external environment into the dosage form regulates the delivery of drug from osmotic device. Osmotic pumps are promising systems for controlled drug delivery. The systems are used for oral administration and implantation. Osmotic pumps consist of an inner core containing drug and coated with a semi permeable membrane.
Keywords: Osmosis, Osmotic drug delivery system, Osmotic pump.
2) "Drug delivery - definition of drug delivery by Medica dictionary". TheFreeDictionary.com.
3) Wang NX, von Recum HA, Affinity-Based Drug Delivery, Macromol Biosci, 2011; 11 (3):321–332.
4) Roco MC, Bainbridge WS, Societal implications of nanoscience and nanotechnology, maximizing human benefit, Journal of Nanoparticle Research, 2005; 7 (1):1-13.
5) Bhagat Babasheb et al, osmotic drug delivery system an overiew jjppr,human, 2014; 2 (1):29-44.
6) Prescott L.F, The need for improved drug delivery in clinical practice, In Novel Drug Delivery and Its Therapeutic application, John Wiley and Sons, West Susset, U.K. 1989; 1-11.
7) Cardinal JR, Controlled release osmotic drug delivery systems for oral applications, Drugs and the Pharmaceutical Sciences, 2000; 102:411-444
8) Rao BS, Kumar NR, Madhuri K, Narayan PS, Murthy KVR, Osmotic drug delivery systems, Eastern Pharmacist, 2001; 44(521):21– 28.
9) Verma RK, Mishra B, Garg S, Osmotically controlled oral drug delivery, Drug Development and Industrial Pharmacy, 2000; 26 (7):695- 708.
10) Rastogi V, Shukla S, Singh R, Lal N, Yadav P, Microspheres: A Promising Drug Carrier. Journal of Drug Delivery and Therapeutics, 2016; 6(3):18-26.
11) Verma RK, Krishna DM, Garg S, Formulation aspects in the development of osmotically controlled oral drug delivery systems, J Control Release, 2002; 79:7-27
12) YANG Xing-Gang, ZHANG Guo-Hua, LI Wei, PENG Bo, LIU Zhi-Dong, PAN Wei-San, Design and Evaluation of Jingzhiguanxin Monolithic Osmotic Pump Tablet, Chem Pharm Bull, 2006; 54(4):465-469.
13) Sastry S, Phanidhar K, Barclay Brian, Osmotic controlled drug delivery system, in Li Xiaoling, Jasti Bhaskara R, Design of Controlled Release Drug Delivery Systems, McGraw-Hill Companies, INC, New York, 2006; 203- 229.
14) Martin A. Phyical Pharmacy, 4th Edition, Lippincott Williams and Wilkin s 1994; 116-117 controlled oral drug delivery system. J. Controlled Release. 2002; 79:7-27.
15) Santus G, Baker RW. J Control Release 1995; 35:2. [ Pfefer WEP. Osmotishe Umtersuchen, Leipzig, 187
16) Rose S, Nelson JF, A continuous long-term injector, The Australian Journal of Experimental Biology and Medical Science, 1955; 33 (4):415-419.
17) T. Higuchi, Osmotic dispenser with collapsible supply container, US Patent No. 3, 760,805, 1973.
18) T. Higuchi, H. M. Leeper, Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient, US Patent No. 3995631, 1976.
19) F. Theeuwes, Osmotic system for delivering selected beneficial agents having varying degrees of solubility, US Patent No. 4111201, 1978
20) R. Cortese, F. Theeuwes, Osmotic device with hydrogel driving member, US Patent No. 4, 327,725, 1982.
21) P. S. I. Wong, B. Barclay, J. C. Deters, F. Theeuwes, Osmotic device with dual thermodynamic activity, US Patent 4612008, 1986
22) Ghosh T, Ghosh A, Drug delivery through osmotic systems an overview, Journal of Applied Pharmaceutical Science, 2011; 2:38-49.
23) D. Ouyang, S. Nie, W. Li, H. Guo, H. Liu, W. Pan, Design and evaluation of compound metformin/glipizide elementary osmotic pump tablets, Journal of Pharmacy and Pharmacology, 2005; 57(7):817-820.
24) Cortese R, Theeuwes F, Osmotic device with hydrogel driving member, US Patent No. 4, 327,725, 1982
25) P. S. I. Wong, B. Barclay, J. C. Deters, F. Theeuwes, Osmotic device with dual thermodynamic activity, US Patent 4612008, 1986.
26) J. L. Haslam and G. S. Rork, Controlled Porosity Osmotic Pump, U.S. Patent No. 4880631, 1989.
27) L. Liu, J. Ku, G. Khang, B. Lee, J. M. Rhee, H. B. Lee, Nifedipine controlled delivery by sandwiched osmotic tablet system, Journal of Controlled Release, 2000; 68(2):145–156.
28) Kumaravelrajan R, Narayanan N, and Suba V, Development and evaluation of controlled porosity osmotic pump for Nifedipine and Metoprolol combination, Lipids in Health and Disease, 2011; 10(51).
29) Eckenhoff B, Theeuwes F, Urquhart J, Osmotically actuated dosage forms for rate-controlled drug delivery, Pharm Technol, 1987; 11:96-105.
30) Jensen JL, Appel LE, Clair JH, Zentner GM, Variables that affect the mechanism of drug release from osmotic pumps coated with acrylate/methacrylate copolymer latexes, J Pharm Sci, 1995; 84 (5):530-533.
31) Sastry S, Phanidhar K, Barclay Brian, Osmotic controlled drug delivery system, in Li Xiaoling, Jasti Bhaskara R, Design of Controlled Release Drug Delivery Systems, McGraw-Hill Companies, INC, New York, 2006; 203-229.
32) Higuchi T, Leeper HM. Improved osmotic dispenser employing magnesium sulfate and magnesium chloride US Patent 3760804, 1973.
33) Thakor RS, Majumdar FD, Patel JK, Rajaput Review GC, Osmotic drug delivery systems current scenario, 2010; 34:771-775.
34) GM Zentner, GS Rork, KJ Himmelstein, US patent 4, 1990,968,507.
35) T. Higuchi, H.M. Leeper, Improved osmotic dispenser employing magnesium sulfate and magnesium chloride, US Patent No. 3,760,804 (1973).
36) T. Higuchi, H.M. Leeper, Improved osmotic dispenser employing magnesium sulfate and magnesium chloride, US Patent No. 3,760,804 (1973).
37) Rastogi SK, Vaya N, Mishra B, East Pharm, 1995; 38:79-82.
38) M.K Jain., Introduction novel drug delivery system, first edition, 2010, ISBN 978-81-85731-53-7:131-132.
39) Kojima H, Yoshihara K, Sawada T, Kondo H and Sako K. 2008
40) Verma RK, Krishna DM and Garg S, Formulated aspects in the development of osmotic polyethylene glycol (PEG) matrix tablets, Eur. J. Pharm. Biopharm, 2011; 70:556-562.
41) Aulton's Pharmaceutics; The Design and Manufacture of Medicines. 3rd ed. Philadelphia, USA: Churchill Livingstone Elsevier, 99-102.
42) R. Cortese, F. Theeuwes, Osmotic device with hydrogel driving member, US Patent No. 4,327,725: 1982.
43) P.S.L. Wong, B.L. Barclay, J.C. Deters, F., Theeuwes, Osmotic device for administering certain drugs, US Patent No. 4,765,989; 1988
44) DiMatteo MR and DiNicola DD, Achieving patient compliance: the psychology of the medical practioners role. New York: Pergamon press; 1982.
45) Singla D, Hari Kumar SL, Nirmala, osmotic pump drug delivery- a novel approach, IJRPC, 2012; 2(2):661-670.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).